92
Views
6
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

The association between metabolic syndrome and infarct size in patients with acute myocardial infarction

, , , , &
Pages 287-293 | Received 25 Nov 2009, Accepted 23 Mar 2010, Published online: 29 Apr 2010
 

Abstract

Background. In patients with the metabolic syndrome, the prevalence of cardiovascular disease, disease-related morbidity and mortality are reported to be significantly higher than in a population without the metabolic syndrome. We investigated the role of metabolic syndrome and related biomarkers as predictors of infarct size in patients with their first myocardial infarction. Methods. This was a cross-sectional sub-study from the 3 months follow-up in the NORwegian Study of DIstrict treatment of ST-Elevation Myocardial Infarction (NORDISTEMI), including 152 consecutive patients, all initially treated with thrombolysis. Infarct size after 3 months was determined by late gadolinium enhanced magnetic resonance imaging, measuring ventricular infarct volume in absolute and relative terms. Results. At 3 months, 33 patients (22%) were categorized as having metabolic syndrome. There was no significant difference in median infarct size between those presenting with and without the metabolic syndrome [relative infarct volume 9.0 (4.8, 15.1) % vs. 8.3 (2.9, 13.6)%, p = 0.34]. Adjusting for possible confounders did not alter the results essentially. Circulating levels of IL-18, CRP and PAI-I activity were significantly higher in patients with the metabolic syndrome while adiponectin concentrations were significantly lower (p ≤ 0.01 for all). None of these variables were associated with myocardial infarct size. Conclusions. No association between the presence of metabolic syndrome and related biomarkers, and the size of the myocardial infarction was apparent in this study population.

Acknowledgements

We are grateful to medical technologists Sissel Åkra and Vibeke Bratseth for skilled technical assistance and biochemical analysis. This work was financially supported by the Scientific Board of the Eastern Norway Health Authority, Hamar, Stein Erik Hagens Foundation for Clinical Heart Research and Ada og Hagbarth Waages Humanitære og Veldedige Stiftelse, Oslo, Norway

Declaration of interest: No competing financial interests exist.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.